These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36756769)

  • 21. Metabolic tumor volume derived from
    Ding C; Mao X; Li N; Huang M; Huang Z; Bao W; Li H; Fan J
    Hell J Nucl Med; 2022; 25(1):63-70. PubMed ID: 35503557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic impact of the
    Goksel S; Cengiz A; Ozturk H; Yurekli Y
    J Cancer Res Ther; 2021; 17(4):925-930. PubMed ID: 34528543
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of prognostic values of primary tumor and nodal
    Lim CH; Hyun SH; Moon SH; Cho YS; Choi JY; Lee KH
    Eur Radiol; 2019 Oct; 29(10):5288-5297. PubMed ID: 30899978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and prognostic role of 2-[
    Tan X; Yuan H; Li D; Sun X; Ding C; Jiang L
    Ann Hematol; 2022 Dec; 101(12):2699-2709. PubMed ID: 36123452
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer.
    Kim K; Kim SJ; Kim IJ; Kim YS; Pak K; Kim H
    Nucl Med Commun; 2012 Jun; 33(6):613-20. PubMed ID: 22407127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.
    Salavati A; Duan F; Snyder BS; Wei B; Houshmand S; Khiewvan B; Opanowski A; Simone CB; Siegel BA; Machtay M; Alavi A
    Eur J Nucl Med Mol Imaging; 2017 Nov; 44(12):1969-1983. PubMed ID: 28689281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The utility of
    Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
    Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New insight on the correlation of metabolic status on
    Wang Y; Zhao N; Wu Z; Pan N; Shen X; Liu T; Wei F; You J; Xu W; Ren X
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1127-1136. PubMed ID: 31502013
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic Value of the Volumetric Parameters of Dual-Time-Point
    Okazaki E; Seura H; Hasegawa Y; Okamura T; Fukuda H
    AJR Am J Roentgenol; 2019 Dec; 213(6):1366-1373. PubMed ID: 31509426
    [No Abstract]   [Full Text] [Related]  

  • 30. Contribution of Metabolic Tumor Volume and Total Lesion Glycolysis to Predict Prognosis in Early-Stage Lung Cancer at Preoperative Staging.
    Karaman E; Goksel S; Tuluce K
    J Coll Physicians Surg Pak; 2022 Jun; 32(6):740-745. PubMed ID: 35686405
    [TBL] [Abstract][Full Text] [Related]  

  • 31.
    Wu X; Huang Y; Li Y; Wang Q; Wang H; Jiang L
    Ann Nucl Med; 2019 Sep; 33(9):647-656. PubMed ID: 31165974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of novel quantitative techniques for fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer.
    Wang D; Koh ES; Descallar J; Pramana A; Vinod SK; Ho Shon I
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):349-358. PubMed ID: 27550522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic significance of metabolic parameters measured by
    Chang H; Lee SJ; Lim J; Lee JS; Kim YJ; Lee WW
    J Cancer Res Clin Oncol; 2019 May; 145(5):1361-1367. PubMed ID: 30900157
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of
    Li Y; Li Y; Huang Y; Wu X; Yang Z; Wu C; Jiang L
    Ann Nucl Med; 2021 Sep; 35(9):1048-1057. PubMed ID: 34101153
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Value of 18F-FDG PET/CT in Surgical Non-Small Cell Lung Cancer: A Meta-Analysis.
    Liu J; Dong M; Sun X; Li W; Xing L; Yu J
    PLoS One; 2016; 11(1):e0146195. PubMed ID: 26727114
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FDG PET/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma.
    Chung HW; Lee KY; Kim HJ; Kim WS; So Y
    J Cancer Res Clin Oncol; 2014 Jan; 140(1):89-98. PubMed ID: 24194352
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential expression and prognostic significance of GLUT1 according to histologic type of non-small-cell lung cancer and its association with volume-dependent parameters.
    Koh YW; Lee SJ; Park SY
    Lung Cancer; 2017 Feb; 104():31-37. PubMed ID: 28212997
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of metabolic tumor volume of pretreatment
    Kumasaka S; Nakajima T; Arisaka Y; Tokue A; Achmad A; Fukushima Y; Shimizu K; Kaira K; Higuchi T; Tsushima Y
    BMC Med Imaging; 2018 Nov; 18(1):46. PubMed ID: 30477476
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
    Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T
    Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of
    Rudžianskas V; Korobeinikova E; Rudžianskienė M; Jaselskė E; Adlienė D; Šedienė S; Kulakienė I; Padervinskis E; Jurkienė N; Juozaitytė E
    Medicina (Kaunas); 2018 Dec; 54(6):. PubMed ID: 30544718
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.